<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Isoniazid</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00951</strong>&#160; (APRD01055, EXPT01940)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis. [PubChem]</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00951/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00951/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00951.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00951.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00951.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00951.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00951.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00951">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>4-pyridinecarbohydrazide</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>INH</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Isonicotinic acid hydrazide</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Isonicotinic hydrazide</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Isonicotinohydrazide</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Isonicotinylhydrazine</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Nicozid</td><td>Piam</td></tr><tr><td>Nidrazid</td><td>Zentiva</td></tr><tr><td>Nydrazid</td><td>Sandoz</td></tr><tr><td>Rimicid</td><td>Sopharma</td></tr><tr><td>Rimifon</td><td>Roche</td></tr><tr><td>Servizid</td><td>Novartis</td></tr><tr><td>Tibinide</td><td>Meda</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="mixtures"><thead><tr><th>Brand Name</th><th>Ingredients</th></tr></thead><tbody><tr><td>IsonaRif</td><td>Isoniazid + Rifampicin</td></tr><tr><td>Isotamine B 300</td><td>Isoniazid + Pyridoxine Hydrochloride</td></tr><tr><td>Rifater</td><td>Isoniazid + Pyrazinamide + Rifampin</td></tr></tbody></table></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/antitubercular-agents">Antitubercular Agents</a></li>
<li><a href="/mesh/fatty-acid-synthesis-inhibitors">Fatty Acid Synthesis Inhibitors</a></li></ul></td></tr><tr><th>CAS number</th><td>54-85-3</td></tr><tr><th>Weight</th><td>Average: 137.1393<br>Monoisotopic: 137.058911861</td></tr><tr><th>Chemical Formula</th><td>C<sub>6</sub>H<sub>7</sub>N<sub>3</sub>O</td></tr><tr><th>InChI Key</th><td>QRXWMOHMRWLFEY-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C6H7N3O/c7-9-6(10)5-1-3-8-4-2-5/h1-4H,7H2,(H,9,10)</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">pyridine-4-carbohydrazide</div></td></tr><tr><th>SMILES</th><td><div class="wrap">NNC(=O)C1=CC=NC=C1</div></td></tr><tr><th>Mass Spec</th><td><a href="/system/mass_specs/DB00951.gif?1265922773">show</a>(8.21 KB)</td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Heterocyclic Compounds</td></tr><tr><th>Class</th><td>Pyridines and Derivatives</td></tr><tr><th>Subclass</th><td>Pyridinecarboxylic Acids and Derivatives</td></tr><tr><th>Direct parent</th><td>Pyridinecarboxylic Acids and Derivatives</td></tr><tr><th>Alternative parents</th><td>Carboxylic Acid Hydrazides; Enolates; Carboxylic Acid Amides; Polyamines; Hydrazines and Derivatives</td></tr><tr><th>Substituents</th><td>carboxamide group; carboxylic acid hydrazide; carboxylic acid derivative; enolate; polyamine; hydrazine derivative; amine; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the pyridinecarboxylic acids and derivatives. These are compounds containing a pyridine ring bearing a carboxylic acid group or a derivative thereof.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the treatment of all forms of tuberculosis in which organisms are susceptible.</td></tr><tr><th>Pharmacodynamics</th><td>Isoniazid is a bactericidal agent active against organisms of the genus Mycobacterium, specifically <i>M. tuberculosis</i>, <i>M. bovis</i> and <i>M. kansasii</i>. It is a highly specific agent, ineffective against other microorganisms. Isoniazid is bactericidal to rapidly-dividing mycobacteria, but is bacteriostatic if the mycobacterium is slow-growing.</td></tr><tr><th>Mechanism of action</th><td>Isoniazid is a prodrug and must be activated by bacterial catalase. Specficially, activation is associated with reduction of the mycobacterial ferric KatG catalase-peroxidase by hydrazine and reaction with oxygen to form an oxyferrous enzyme complex. Once activated, isoniazid inhibits the synthesis of mycoloic acids, an essential component of the bacterial cell wall. At therapeutic levels isoniazid is bacteriocidal against actively growing intracellular and extracellular <i>Mycobacterium tuberculosis</i> organisms. Specifically isoniazid inhibits InhA, the enoyl reductase from <i>Mycobacterium tuberculosis</i>, by forming a covalent adduct with the NAD cofactor. It is the INH-NAD adduct that acts as a slow, tight-binding competitive inhibitor of InhA.</td></tr><tr><th>Absorption</th><td>Readily absorbed following oral administration; however, may undergo significant first pass metabolism. Absorption and bioavailability are reduced when isoniazid is administered with food.</td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td>Very low (0-10%)</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Primarily hepatic. Isoniazid is acetylated by N -acetyl transferase to N -acetylisoniazid; it is then biotransformed to isonicotinic acid and monoacetylhydrazine. Monoacetylhydrazine is associated with hepatotoxicity via formation of a reactive intermediate metabolite when N-hydroxylated by the cytochrome P450 mixed oxidase system. The rate of acetylation is genetically determined. Slow acetylators are characterized by a relative lack of hepatic N -acetyltransferase.</p></td></tr><tr><th>Route of elimination</th><td>From 50 to 70 percent of a dose of isoniazid is excreted in the urine within 24 hours.</td></tr><tr><th>Half life</th><td>Fast acetylators: 0.5 to 1.6 hours. Slow acetylators: 2 to 5 hours.</td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td>LD<sub>50</sub> 100 mg/kg (Human, oral). Adverse reactions include rash, abnormal liver function tests, hepatitis, peripheral neuropathy, mild central nervous system (CNS) effects. In vivo, Isoniazid reacts with pyridoxal to form a hydrazone, and thus inhibits generation of pyridoxal phosphate. Isoniazid also combines with pyridoxal phosphate; high doses interfere with the coenzyme function of the latter.</td></tr><tr><th>Affected organisms</th><td><ul><li>Mycobacteria</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="snp-fx"><thead><tr><th>Interacting Gene/Enzyme</th><th>SNP RS ID</th><th>Allele name</th><th>Defining change</th><th>Adverse Reaction</th><th>Reference(s)</th></tr></thead><tbody><tr><td>Cytochrome P450 2E1<br>Gene symbol: CYP2E1<br>UniProt: <a class="wishart-link-out" href="http://www.uniprot.org/uniprot/P05181" target="_blank">P05181 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><a class="wishart-link-out" href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=rs6413419" target="_blank">rs6413419 <span class="glyphicon glyphicon-new-window"> </span></a></td><td>CYP2E1 *1A</td><td>G Allele, homozygote</td><td>Hepatotoxicity</td><td><span class="citation"><a class="pubmed-link wishart-link-out" data-toggle="tooltip" href="http://www.ncbi.nlm.nih.gov/pubmed/16770646" target="_blank" title="Vuilleumier N, Rossier MF, Chiappe A, Degoumois F, Dayer P, Mermillod B, Nicod L, Desmeules J, Hochstrasser D: CYP2E1 genotype and isoniazid-induced hepatotoxicity in patients treated for latent tuberculosis. Eur J Clin Pharmacol. 2006 Jun;62(6):423-9. Epub 2006 Apr 27.">16770646 <span class="glyphicon glyphicon-new-window"> </span></a></span></td></tr></tbody></table></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9892</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9895</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.6959</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Non-substrate
        </td>
        <td>0.8315</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9778</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.996</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9054</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.9088</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.9116</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.7557</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Inhibitor</td>
        <td>0.6482</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9273</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9443</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9513</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.5111</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.9342</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          AMES toxic 
        </td>
        <td>
            0.8557
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.7514
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.981
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.0713 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9872
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.9586
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Sandoz canada inc</li>
<li>Sandoz inc</li>
<li>Hoffmann la roche inc</li>
<li>Carolina medical products co</li>
<li>Mikart inc</li>
<li>Lannett co inc</li>
<li>Dow pharmaceutical corp sub dow chemical co</li>
<li>Medpointe pharmaceuticals medpointe healthcare inc</li>
<li>Novartis pharmaceuticals corp</li>
<li>Barr laboratories inc</li>
<li>Duramed pharmaceuticals inc sub barr laboratories inc</li>
<li>Halsey drug co inc</li>
<li>Impax laboratories inc</li>
<li>Ivax pharmaceuticals inc sub teva pharmaceuticals usa</li>
<li>Eli lilly and co</li>
<li>Mk laboratories inc</li>
<li>Mutual pharmaceutical co inc</li>
<li>Nexgen pharma inc</li>
<li>Panray corp sub ormont drug and chemical co inc</li>
<li>L perrigo co</li>
<li>Pharmavite pharmaceuticals</li>
<li>Phoenix laboratories inc</li>
<li>Purepac pharmaceutical co</li>
<li>Watson laboratories inc</li>
<li>West ward pharmaceutical corp</li>
<li>Whiteworth towne paulsen inc</li>
<li>Bristol myers squibb co</li>
<li>Everylife</li></ul></td></tr><tr><th>Packagers</th><td><ul><li>Advanced Pharmaceutical Services Inc.</li>
<li><a href="http://www.aidarex.com">Aidarex Pharmacuticals LLC</a></li>
<li>Amend</li>
<li><a href="http://www.amneal.com">Amneal Pharmaceuticals</a></li>
<li>Apotheca Inc.</li>
<li><a href="http://orders.a-smeds.com">A-S Medication Solutions LLC</a></li>
<li>Barr Pharmaceuticals</li>
<li><a href="http://www.bpipack.com">Blenheim Pharmacal</a></li>
<li><a href="http://www.bms.com">Bristol-Myers Squibb Co.</a></li>
<li><a href="http://bryantranchprepack.com">Bryant Ranch Prepack</a></li>
<li><a href="http://www.carolinamedical.com">Carolina Medical Products Co.</a></li>
<li>Consolidated Midland Corp.</li>
<li>Dept Health Central Pharmacy</li>
<li>Direct Dispensing Inc.</li>
<li><a href="http://www.drxdispensing.com">Dispensing Solutions</a></li>
<li>E.R. Squibb and Sons LLC</li>
<li>Eon Labs</li>
<li><a href="http://www.gsms.us">Golden State Medical Supply Inc.</a></li>
<li><a href="http://hjharkinscompanyinc.com">H.J. Harkins Co. Inc.</a></li>
<li>Heartland Repack Services LLC</li>
<li><a href="http://www.huffmanlabs.com">Huffman Laboratories</a></li>
<li>Liberty Pharmaceuticals</li>
<li><a href="http://www.majorpharmaceuticals.com">Major Pharmaceuticals</a></li>
<li><a href="http://www.unitdosesupply.com">Murfreesboro Pharmaceutical Nursing Supply</a></li>
<li><a href="http://www.nexgenpharma.com">Nexgen Pharma Inc.</a></li>
<li><a href="http://www.nucarerx.com">Nucare Pharmaceuticals Inc.</a></li>
<li>PCA LLC</li>
<li><a href="http://www.pdrx.com">PD-Rx Pharmaceuticals Inc.</a></li>
<li><a href="http://www.pharmpakinc.com">Pharmpak Inc.</a></li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li><a href="http://www.preferredpharmaceuticals.com">Preferred Pharmaceuticals Inc.</a></li>
<li>Prepackage Specialists</li>
<li><a href="http://www.prepaksys.com">Prepak Systems Inc.</a></li>
<li><a href="http://www.remedyrepack.com">Remedy Repack</a></li>
<li><a href="http://www.sandhillspackaging.com">Sandhills Packaging Inc.</a></li>
<li><a href="http://www.sandoz.ca">Sandoz</a></li>
<li><a href="http://www.sanofi-aventis.com">Sanofi-Aventis Inc.</a></li>
<li><a href="http://www.southwoodhealthcare.com">Southwood Pharmaceuticals</a></li>
<li><a href="http://www.udllabs.com">UDL Laboratories</a></li>
<li><a href="http://www.versapharm.com">Versapharm Inc.</a></li>
<li><a href="http://www.west-ward.com">West-Ward Pharmaceuticals</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Powder</td><td>Oral</td><td></td></tr><tr><td>Syrup</td><td>Oral</td><td></td></tr><tr><td>Tablet</td><td>Oral</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB01418">Acenocoumarol</a></td><td>Isoniazid may increase the anticoagulant effect of acenocoumarol.</td></tr><tr><td><a href="/drugs/DB00316">Acetaminophen</a></td><td>Risk of hepatotoxicity</td></tr><tr><td><a href="/drugs/DB01223">Aminophylline</a></td><td>Isoniazid may increase the effect and toxicity of oxtriphylline.</td></tr><tr><td><a href="/drugs/DB01125">Anisindione</a></td><td>Isoniazid may increase the anticoagulant effect of anisindione.</td></tr><tr><td><a href="/drugs/DB01558">Bromazepam</a></td><td>Isoniazid, a strong CYP3A4 inhibitor, may increase the serum concentration of bromazepam by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of bromazepam if isoniazid is initiated, discontinued or dose changed. Dosage adjustments may be required. </td></tr><tr><td><a href="/drugs/DB00564">Carbamazepine</a></td><td>Carbamazepine effect is increased as is isoniazid toxicity</td></tr><tr><td><a href="/drugs/DB00395">Carisoprodol</a></td><td>Strong CYP2C19 inhibitors such as isoniazid may decrease the metabolism of CYP2C19 substrates such as carisoprodol. Consider an alternative for one of the interacting drugs in order to avoid toxicity of the substrate. Some combinations are specifically contraindicated by manufacturers. Suggested dosage adjustments are also offered by some manufacturers. Please review applicable package inserts. Monitor for increased effects of the CYP substrate if a CYP inhibitor is initiated/dose increased, and decreased effects if a CYP inhibitor is discontinued/dose decreased.</td></tr><tr><td><a href="/drugs/DB01219">Dantrolene</a></td><td>Isoniazid may increase the serum concentration of dantrolene by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dantrolene if isoniazid is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB00266">Dicoumarol</a></td><td>Isoniazid may increase the anticoagulant effect of dicumarol.</td></tr><tr><td><a href="/drugs/DB00822">Disulfiram</a></td><td>Increased risk of CNS adverse effects</td></tr><tr><td><a href="/drugs/DB00651">Dyphylline</a></td><td>Increases the effect and toxicity of theophylline</td></tr><tr><td><a href="/drugs/DB06210">Eltrombopag</a></td><td>Affects hepatic CYP1A2 metabolism, increases Eltrombopag level or affect.</td></tr><tr><td><a href="/drugs/DB00754">Ethotoin</a></td><td>Isoniazid increases the effect of phenytoin in 20% of patients</td></tr><tr><td><a href="/drugs/DB01320">Fosphenytoin</a></td><td>Isoniazid may increase the effect of phenytoin in 20% of patients.</td></tr><tr><td><a href="/drugs/DB01026">Ketoconazole</a></td><td>Isoniazid decreases the effect of ketoconazole</td></tr><tr><td><a href="/drugs/DB00532">Mephenytoin</a></td><td>Isoniazid increases the effect of phenytoin in 20% of patients</td></tr><tr><td><a href="/drugs/DB01303">Oxtriphylline</a></td><td>Isoniazid may increase the effect and toxicity of oxtriphylline.</td></tr><tr><td><a href="/drugs/DB00454">Pethidine</a></td><td>Possible episodes of hypotension</td></tr><tr><td><a href="/drugs/DB00252">Phenytoin</a></td><td>Isoniazid increases the effect of phenytoin in 20% of patients</td></tr><tr><td><a href="/drugs/DB00864">Tacrolimus</a></td><td>The strong CYP3A4 inhibitor, Isoniazid, may decrease the metabolism and clearance of Tacrolimus, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Tacrolimus if Isoniazid is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00820">Tadalafil</a></td><td>Isoniazid may reduce the metabolism of Tadalafil. Concomitant therapy should be avoided if possible due to high risk of Tadalafil toxicity.</td></tr><tr><td><a href="/drugs/DB00675">Tamoxifen</a></td><td>Isoniazid may increase the serum concentration of Tamoxifen by decreasing its metabolism and clearance. Isoniazid may also decrease the therapeutic effect of Tamoxifen by decreasing active metabolite production. Monitor for changes in the therapeutic/adverse effects of Tamoxifen if Isoniazid is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00706">Tamsulosin</a></td><td>Isoniazid, a CYP3A4/2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4/2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Isoniazid is initiated, discontinued, or dose changed.</td></tr><tr><td><a href="/drugs/DB00976">Telithromycin</a></td><td>Isoniazid may increase the plasma concentration of Telithromycin. Consider alternate therapy or monitor therapeutic/adverse effects.</td></tr><tr><td><a href="/drugs/DB06287">Temsirolimus</a></td><td>Isoniazid may inhibit the metabolism and clearance of Temsirolimus. Concomitant therapy should be avoided. </td></tr><tr><td><a href="/drugs/DB00444">Teniposide</a></td><td>The strong CYP3A4 inhibitor, Isoniazid, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Isoniazid is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00277">Theophylline</a></td><td>Isoniazid may increase the therapeutic and adverse effects of theophylline.</td></tr><tr><td><a href="/drugs/DB00906">Tiagabine</a></td><td>The strong CYP3A4 inhibitor, Isoniazid, may decrease the metabolism and clearance of Tiagabine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Tiagabine if Isoniazid is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB01036">Tolterodine</a></td><td>Isoniazid may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.</td></tr><tr><td><a href="/drugs/DB00193">Tramadol</a></td><td>Isoniazid may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. Isoniazid may decrease the effect of Tramadol by decreasing active metabolite production. </td></tr><tr><td><a href="/drugs/DB00656">Trazodone</a></td><td>The CYP3A4 inhibitor, Isoniazid, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Consider alternate therapy or monitor for changes in Trazodone efficacy/toxicity if Isoniazid is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB00726">Trimipramine</a></td><td>The strong CYP3A4/CYP2C19 inhibitor, Isoniazide, may decrease the metabolism and clearance of Trimipramine, a CYP3A4/CYP2C19 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimipramine if Isoniazid is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB00862">Vardenafil</a></td><td>Isoniazid, a strong CYP3A4 inhibitor, may reduce the metabolism and clearance of Vardenafil. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Vardenafil.</td></tr><tr><td><a href="/drugs/DB00285">Venlafaxine</a></td><td>Isoniazid, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Isoniazid is initiated, discontinued, or dose changed.</td></tr><tr><td><a href="/drugs/DB00661">Verapamil</a></td><td>Isoniazid, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Isoniazid is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB00570">Vinblastine</a></td><td>Isoniazid, a strong CYP3A4 inhibitor, may decrease the metabolism of Vinblastine. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of Vinblastine if Isoniazid is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00541">Vincristine</a></td><td>Isoniazid, a strong CYP3A4 inhibitor, may increase the serum concentration of Vincristine by decreasing its metabolism. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Isoniazid is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00361">Vinorelbine</a></td><td>Isoniazid, a strong CYP3A4 inhibitor, may increase the serum concentration of Vinorelbine by decreasing its metabolism. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Isoniazid is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00682">Warfarin</a></td><td>Isoniazid may increase the anticoagulant effect of warfarin.</td></tr><tr><td><a href="/drugs/DB00425">Zolpidem</a></td><td>Isoniazid, a strong CYP3A4 inhibitor, may increase the serum concentration of zolpidem by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zolpidem if isoniazid is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB00909">Zonisamide</a></td><td>Isoniazid, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if isoniazid is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB01198">Zopiclone</a></td><td>Isoniazid, a strong CYP3A4 inhibitor, may increase the serum concentration of zopiclone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if isoniazid is initiated, discontinued or dose changed.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Avoid aged foods (cheese, red wine), pickled foods, cured foods (bacon/ham), chocolate, fava beans, beer, unless approved by your physician.</li>
<li>Avoid alcohol.</li>
<li>Do not take calcium, aluminum, magnesium or Iron supplements within 2 hours of taking this medication.</li>
<li>Increase dietary intake of magnesium, folate, vitamin B6, B12, and/or consider taking a multivitamin.</li>
<li>Take on empty stomach: 1 hour before or 2 hours after meals.</li>
<li>Take with a full glass of water.</li></ul></td></tr></tbody></table>